Global Prostate Cancer Market Size , Share , Analysis , Forecast , Industry Strategy , Opportunity , Trends , Insights , Growth , Price , Research Survey , Segment , Outlook and Challenges Report To 2023
Global Prostate Cancer Market Size , Share , Analysis , Forecast , Industry Strategy , Opportunity , Trends , Insights , Growth , Price , Research Survey , Segment , Outlook and Challenges Report To 2023
Increase in prevalence of Prostate cancer and availability of new treatment options ( Zytiga , Xtandi , Cabazitaxel and Xofigo ) in last few years has extended role of newer oral Antiandrogens to treat metastatic CRPC patient populations where the unmet need was high . This has expanded WW market size of Prostate cancer drugs to $ 7b in 2016 from $ 2.5b in 2011 . Now nmCRPC , HSPC and Xtandi / Zytiga resistance population are the markets where in new pipeline drugs are under development .
Reported PhII clinical data of Xtandi , ARN-509 and ODM-201 in nmCRPC when indirectly compared demonstrate the bar is high for ARN-509 to compete against Xtandi in nmCRPC market and while ODM-201 is few years behind in clinical development . While in mHSPC reported clinical results of STAMPEDE study opens door for docetaxel combination approach as standard of care in first line setting .
Around 8 plus drugs are in PhIII development for Prostate cancer treatment and 26 plus drugs are in PhII development ( 21 small molecules ) - success of a few ( ARN-509 , ODM-201 , AZD 5363 , GX301 ) in coming years will expand nmCRPC ($ 3.5be ), mHSPC market ($ 1be ) and Xtandi / Zytiga resistant population ($ 1be ) market by 2023 . Longer duration of therapy and high